Free Trial

Reprogrammed Interchange Llc Sells 48,884 Shares of Vor Biopharma (NASDAQ:VOR) Stock

Vor Biopharma logo with Manufacturing background

Key Points

  • Reprogrammed Interchange Llc sold 48,884 shares of Vor Biopharma at an average price of $32.07, totaling approximately $1.57 million, which decreased their ownership by 3.43%.
  • Vor Biopharma's shares traded down 1.5% to $31.23, and the company has a market capitalization of $214.05 million.
  • Despite a recent quarterly loss, analysts have mixed ratings on Vor Biopharma’s stock, with a consensus rating of "Hold" and a target price of $113.83.
  • MarketBeat previews the top five stocks to own by November 1st.

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) major shareholder Reprogrammed Interchange Llc sold 48,884 shares of the firm's stock in a transaction on Thursday, October 9th. The shares were sold at an average price of $32.07, for a total value of $1,567,709.88. Following the sale, the insider directly owned 1,374,775 shares of the company's stock, valued at $44,089,034.25. This represents a 3.43% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.

Reprogrammed Interchange Llc also recently made the following trade(s):

  • On Wednesday, October 8th, Reprogrammed Interchange Llc sold 75,262 shares of Vor Biopharma stock. The shares were sold at an average price of $33.87, for a total value of $2,549,123.94.
  • On Tuesday, October 7th, Reprogrammed Interchange Llc sold 27,624 shares of Vor Biopharma stock. The shares were sold at an average price of $33.84, for a total value of $934,796.16.
  • On Monday, October 6th, Reprogrammed Interchange Llc sold 70,763 shares of Vor Biopharma stock. The shares were sold at an average price of $37.01, for a total value of $2,618,938.63.
  • On Friday, October 3rd, Reprogrammed Interchange Llc sold 7,901 shares of Vor Biopharma stock. The shares were sold at an average price of $37.83, for a total value of $298,894.83.
  • On Thursday, October 2nd, Reprogrammed Interchange Llc sold 32,451 shares of Vor Biopharma stock. The shares were sold at an average price of $39.83, for a total value of $1,292,523.33.
  • On Wednesday, October 1st, Reprogrammed Interchange Llc sold 1,400 shares of Vor Biopharma stock. The stock was sold at an average price of $39.19, for a total value of $54,866.00.
  • On Tuesday, September 16th, Reprogrammed Interchange Llc sold 447,278 shares of Vor Biopharma stock. The stock was sold at an average price of $1.54, for a total value of $688,808.12.
  • On Tuesday, September 16th, Reprogrammed Interchange Llc sold 22,363 shares of Vor Biopharma stock. The stock was sold at an average price of $30.80, for a total value of $688,780.40.
  • On Monday, September 15th, Reprogrammed Interchange Llc sold 20,000 shares of Vor Biopharma stock. The stock was sold at an average price of $32.80, for a total value of $656,000.00.
  • On Friday, September 12th, Reprogrammed Interchange Llc sold 15,000 shares of Vor Biopharma stock. The stock was sold at an average price of $35.00, for a total value of $525,000.00.

Vor Biopharma Trading Down 1.5%

Shares of VOR traded down $0.49 during midday trading on Friday, reaching $31.23. 396,470 shares of the stock were exchanged, compared to its average volume of 391,530. Vor Biopharma Inc. has a twelve month low of $2.62 and a twelve month high of $65.80. The stock has a market capitalization of $214.05 million, a P/E ratio of -0.11 and a beta of 2.07. The firm has a 50 day moving average of $37.73.

Vor Biopharma (NASDAQ:VOR - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($43.60) EPS for the quarter, missing analysts' consensus estimates of ($11.40) by ($32.20).

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on VOR shares. Zacks Research upgraded Vor Biopharma from a "strong sell" rating to a "hold" rating in a research report on Wednesday, September 10th. Wedbush restated an "outperform" rating on shares of Vor Biopharma in a research report on Thursday, June 26th. HC Wainwright restated a "buy" rating and issued a $60.00 price target on shares of Vor Biopharma in a research report on Thursday, August 14th. Wall Street Zen cut Vor Biopharma to a "strong sell" rating in a research report on Saturday, June 28th. Finally, Stifel Nicolaus upgraded Vor Biopharma from a "hold" rating to a "buy" rating and set a $55.00 target price on the stock in a research report on Wednesday, September 24th. Five equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $113.83.

Check Out Our Latest Research Report on VOR

Hedge Funds Weigh In On Vor Biopharma

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. OMERS ADMINISTRATION Corp bought a new position in shares of Vor Biopharma during the 1st quarter worth approximately $100,000. Goldman Sachs Group Inc. raised its position in shares of Vor Biopharma by 218.2% during the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock worth $61,000 after purchasing an additional 58,247 shares during the period. Money Concepts Capital Corp raised its position in Vor Biopharma by 106.1% in the 1st quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock valued at $37,000 after buying an additional 26,535 shares during the last quarter. Jane Street Group LLC purchased a new stake in Vor Biopharma in the 1st quarter valued at $140,000. Finally, XTX Topco Ltd purchased a new stake in Vor Biopharma in the 2nd quarter valued at $66,000. 97.29% of the stock is owned by institutional investors and hedge funds.

Vor Biopharma Company Profile

(Get Free Report)

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.

See Also

Insider Buying and Selling by Quarter for Vor Biopharma (NASDAQ:VOR)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Vor Biopharma Right Now?

Before you consider Vor Biopharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vor Biopharma wasn't on the list.

While Vor Biopharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report
Like this article? Share it with a colleague.